Patients with have Crohn’s disease and multiple sclerosis often use Tysabri drug as administering for intravenous infusion every several days (i.e. every 28 days).

This drug claimed have improvement the quality of life for multiple sclerosis patient and increase rate of remission including prevent relapse in Crohn’s disease.

However recent updated from FDA notified to healthcare professionals and patients that this drug have potential risk of developing progressive multifocal leukoecephalopathy (PML).

This warning based on report received by FDA about 31 confirmed cases of PML as of January 21, 2010 due to the occurrence of Immune Reconstitution Inflammatory Syndrome (IRIS) which characterized by severe inflammatory response that can occur during or following immune system recovery caused an unexpected decline in patients condition after return of immune function.

Patient who develops PML should discontinued use of Tysabri and clinicians should pay attention related to their prescribing.

Related posts:

1. Another disorder possible linked to migraine in women, multiple sclerosis In this latest analysis founded that women with have migraine...
2. About multiple sclerosis, signs and symptoms, diagnosing and causes Multiple Sclerosis (MS) is a Central Nervous System (CNS) inflammation....
3. Improvement in urinary dysfunction both incontinence and retention for patients with multiple sclerosis through physical therapy There is pharmacotherapy to treats patients with Multiple Sclerosis who...
4. Homeopathic remedies for multiple sclerosis disease The onset of this disease that affect to the nerves...
5. Unimprovement of hospitalized among CA-Pneumonia patient with had corticosteroid medication Prednisolone 40 mg Patient who had community-acquired pneumonia (CAP), asthma, rheumatoid arthritis, chron’s...

Visitor Guidance :::MOUSE OVER YOUR POINTER TO THE HOMEOPATHIC AND NATURAL IMAGE PRODUCTS FOR SHORT PRODUCTS DESCRIPTION (YOUR JAVASCRIPT BROWSER MUST BE ENABLE) OR SEE IN ABOVE SUB-CATEGORIES::: Return to HOMEPAGE.